Investigational drug · Phase 2
ION775
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertriglyceridemia, Severe Hypertriglyceridemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ION775"
First trial start
2026
May 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ION775", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertriglyceridemia
- Severe Hypertriglyceridemia
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ION775" as an intervention, largest first.
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07604974 · 72 participants (planned) · Start May 12, 2026 · Primary completion Sep 2027
Drug: ION775 · For: Hypertriglyceridemia; Severe Hypertriglyceridemia
Sites: Lincoln, California; Aurora, Colorado; Boca Raton, Florida · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia.
Tsimikas S, Morgan E, Sharma J, et al. · J Clin Lipidol 2026
Also in development for Hypertriglyceridemia
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
- DR10624Phase 35 trials
Zhejiang Doer Biologics Co., Ltd. · Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)
- MAR001Phase 23 trials
Marea Therapeutics · Hypertriglyceridemia
- RBD5044Phase 22 trials
Ribocure Pharmaceuticals AB · Dyslipidemias, Hypertriglyceridemia
- JMT202Phase 21 trial
Shanghai JMT-Bio Inc. · Hypertriglyceridemia
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- RN0361Phase 21 trial
Ikaria Bioscience Pty Ltd · Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.